Additionally, at day 90, GEMCOVAC-19 and GEMCOVAC-OM had significantly higher IFNγ+CD4+ T cells (P = 0.001 and P = 0.0465, respectively) and IFNγ+CD8+ T cells (P = 0.0002 and P = 0.0027, respectively) compared with baseline. This evidence concerns the gene CD4 and ocular melanoma.